Modality
Degrader
MOA
SHP2i
Target
APOC3
Pathway
Checkpoint
PsoriasisMigraine
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
Nov 2018
→ Feb 2027
Phase 2Current
NCT06295582
2,595 pts·Psoriasis
2018-11→2025-08·Terminated
NCT08641842
1,298 pts·Migraine
2025-01→2027-02·Completed
3,893 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-167mo agoPh3 Readout· Psoriasis
2027-02-1110mo awayPh3 Readout· Migraine
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2/3
Termina…
P2/3
Complet…
Catalysts
Ph3 Readout
2025-08-16 · 7mo ago
Psoriasis
Ph3 Readout
2027-02-11 · 10mo away
Migraine
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06295582 | Phase 2/3 | Psoriasis | Terminated | 2595 | DOR |
| NCT08641842 | Phase 2/3 | Migraine | Completed | 1298 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Doxacagene | Sanofi | Approved | PSMA | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| Daratuximab | BioMarin | Phase 1 | PRMT5 |